comparemela.com

Latest Breaking News On - Larisaj geskin - Page 1 : comparemela.com

Pandemic Delayed Treatment in Patients With CTCL, Study Finds

VP&S Academy of Clinical Excellence Inducts Fifth Class

VP&S Academy of Clinical Excellence Inducts Fifth Class
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

VP&S Academy of Clinical Excellence To Induct Fifth Class

VP&S Academy of Clinical Excellence To Induct Fifth Class
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy . Helsinn Healthcare S.A.February 18, 2021 GMT Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the use of mechlorethamine gel 0.016% as a topical treatment of early stage mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”).  Mechlorethamine gel 0.016%, also known as chlormethine gel, is approved for use in multiple countries including the US and EU and is marketed under the trade names VALCHLOR® and LEDAGA®. The authorized use for each country varies based on the design of the registrational trial and the individual hea

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.